Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters











Database
Type of study
Language
Publication year range
1.
Med Arch ; 74(1): 8-13, 2020 Feb.
Article in English | MEDLINE | ID: mdl-32317827

ABSTRACT

INTRODUCTION: The high world prevalence of rhinosinusitis (RS) initiates the ways of a favorable search for effective and safe medicines for its pathogenetic treatment. The important part of this process is the choice of the most comfortable dosage form, which will enhance therapeutic compliance and ensure the appropriate medicine efficacy and safety. AIM: To substantiate the efficacy of a new nasal spray with anti-inflammatory properties containing Enisamium Iodide (EI) at a concentration of 10 mg/mL by histomorphological study of the nasal cavity and paranasal sinuses mucosal in rabbits with experimental rhinosinusitis (ERS). METHODS: EI (nasal spray) was a test object. Sinupret® was a reference drug. ERS was induced in rabbits on the first day of the study by tamponade of the right half of the nasal cavity under general anesthesia. The study was performed using 24 rabbits (4 groups, 6 rabbits in each group). The histomorphological examination was performed on the 25th day of the study by the standard light microscopy methods. RESULTS: The histomorphological examination of EI 10 mg/mL (nasal spray) impact on RS in rabbits, which administered during 10 days intranasally, revealed the significant therapeutic effect presented by reduced inflammation signs in the epithelium of the nasal cavities and paranasal sinuses mucosal. Besides, the EI impact was not inferior to the reference drug Sinupret® in tablets. The study of the pharmacological properties of the EI (nasal spray) on ERS showed the high rate of onset of EI actions when used intranasally which was superior to the rate of actions of the reference drug Sinupret® (tablets) administered intragastrically. CONCLUSION: The EI (nasal spray) is a promising drug for a pathogenetic therapy of acute RS, which demands further pre-clinical and clinical studies aiming to substantiate its implementation to the clinical practice.


Subject(s)
Anti-Inflammatory Agents/therapeutic use , Nasal Cavity/anatomy & histology , Nasal Cavity/drug effects , Nasal Sprays , Plant Extracts/therapeutic use , Pyridinium Compounds/therapeutic use , Rhinitis/drug therapy , Sinusitis/drug therapy , Administration, Intranasal , Animals , Anti-Inflammatory Agents/administration & dosage , Humans , Models, Animal , Rabbits
2.
Ceska Slov Farm ; 68(4): 173-179, 2019.
Article in English | MEDLINE | ID: mdl-31822110

ABSTRACT

The article presents the results of the study of the nephroprotective effect of N-acetylglucosamine (NAG) under the development of experimental acute kidney injury (AKI). The study was conducted on a model of acute glycerol nephrosis in rats. NAG was studied at a dose of 50 mg/kg at daily parenteral administration during 1 week compared to quercetin, which was administered intraperitoneally at a dose of 34 mg/kg. The efficiency of the drugs was assessed by the functional state of animals, the renal excretory function and the nitrogen metabolism indices. The NAG effect on rats with AKI caused a reduction of the mortality rate, an increase in diuresis, a reduction of proteinuria, an increase in creatinine and urea excretion, which indicates the normalization of the renal excretory function and nitrogen metabolism. At the same time, NAG has statistically significantly exceeded the effect of quercetin in the majority of indices and, therefore, the level of efficiency. Thus, NAG is an efficient agent for AKI treatment, which can be used at parenteral route of administration.


Subject(s)
Acetylglucosamine/pharmacology , Acute Kidney Injury/drug therapy , Animals , Creatinine/urine , Diuresis , Proteinuria , Quercetin/pharmacology , Rats , Urea/urine
SELECTION OF CITATIONS
SEARCH DETAIL